May 14th 2025
Financial toxicity can affect patient outcomes and quality of life. For example, a patient may forgo treatment or medications to save money, or they may incur high medical debt or go into bankruptcy to pay for medical care.
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
View More
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
Microplastics, Diet and More: What’s Causing Early-Onset Cancer?
March 18th 2025In a February 2025 Time magazine cover story, Jamie Ducharme reports on this atypical and disquieting trend. Ducharme cites a 79% increase in early-onset cancer diagnoses and a 28% increase in cancer-related deaths in this age group from 1990 to 2019.
Read More
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
March 13th 2025In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
Read More
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
CIBMTR Ranks Cedars-Sinai Cancer Among Top Transplant Programs in the U.S.
February 9th 2025Cedars-Sinai was one of 12 among 172 adult transplant centers in the U.S. with a one-year patient post-transplant survival rate above the expected outcome. In 2024, the survival rate for Cedars-Sinai was 90% versus the expected rate of 68% to 83%.
Read More
FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma
January 27th 2025The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More